1. Glaukos receives EU certification for iStent infinite® and other MIGS technologies. 2. This approval enhances GKOS's market position and potential revenue growth.
Achieving regulatory certification can lead to increased sales and market trust. Historical precedents show FDA or EU approvals can significantly boost stock prices in medical technology.
The certification is critical for GKOS, as it directly influences its competitive edge and revenue potential in the EU market.
The EU certification opens new market opportunities and may drive sustained revenue growth over time. This follows a trend where similar certifications positively affect companies' long-term performance.